CTKBCytek Biosciences, Inc.
$5.37+42% 1Y
$5.37
$3.3652 weeks$6.09
CTKB in its own filings
CTKB's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
86
Events found in the filings · across 461 filings · the record starts in 2021
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 29, 2026
Most recent filing · Form 8-K
- Record starts
- May 18, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Late periodic report2 occurrences
- 2024-03-01
- SEC comment-letter activity6 occurrences
- 2021-07-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 29, 2026On September 23, 2026, the board of directors of Cytek Biosciences, Inc. (the “Company”) unanimously adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.Charter/bylaw amendment or fiscal-year change · Form 8-K
- Aug 24, 2026On August 21, 2026, the Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company’s favor on three of the four asserted patent claims, finding noninfringement and …Regulation FD disclosure · Form 8-K
- Aug 5, 2026Cytek Biosciences Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 15, 2026As previously disclosed, Valerie Barnett’s position as Chief Legal Officer and Corporate Secretary of Cytek Biosciences, Inc. (the “Company”) terminated on June 29, 2026.Director or officer change · Form 8-K
- Jun 25, 2026On June 18, 2026, Valerie Barnett and Cytek Biosciences, Inc. (the “Company”) agreed that Ms. Barnett’s position as Chief Legal Officer and Corporate Secretary of the Company would terminate effective as of June 29, 2026.Director or officer change · Form 8-K
- Jun 2, 2026On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity.Director or officer change · Form 8-K
- May 7, 2026Cytek Biosciences Reports First Quarter 2026 Financial Results.Earnings release · press release
- Feb 26, 2026Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results.Earnings release · press release
- Jan 13, 2026Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results.Earnings release · press release
- Nov 5, 2025Cytek Biosciences Reports Third Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…